Clinical
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study
Summary
This multicenter real-world study investigated histologic transformation to small-cell lung cancer (SCLC) in EGFR-mutant non-small cell lung cancer (NSCLC) patients, an aggressive resistance mechanism to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The study included 59 patients and found that adding immunotherapy (atezolizumab, durvalumab) to carboplatin and etoposide (CE) after transformation was associated with significantly improved post-transformation overall survival (17.0 months versus 9.0 months with CE alone). These findings suggest that immunotherapy may be beneficial in this setting, challenging prior evidence. Systematic re-biopsy is highlighted as crucial to confirm transformation and guide treatment.
Critical appraisal
This multicenter retrospective real-world study, involving 59 patients, highlights a significant clinical benefit from adding immune checkpoint inhibitors (ICIs) to chemotherapy (carboplatin and etoposide) for EGFR-mutant NSCLC patients who undergo histologic transformation to SCLC. The observed HR of 0.327 (95% CI: 0.139-0.767) and the improvement in post-transformation overall survival from 9.0 to 17.0 months are clinically meaningful findings. These data, although retrospective, challenge previous evidence of immunotherapy inefficacy in this subgroup and could justify prospective randomized trials to confirm these observations. Clinical practice may evolve towards systematic re-biopsy upon progression on EGFR-TKI therapy to detect transformation and consider this therapeutic combination, with a potential clinical impact in the medium term (3-5 years) if prospective studies validate these results.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology